Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Thermo Fisher Spent $314M on Two Acquisitions in Q1; Settled IP Suits With Roche 454, Illumina

Thermo Fisher Spent $314M on Two Acquisitions in Q1; Settled IP Suits With Roche 454, Illumina

May 11, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Thermo Fisher Scientific disclosed in a filing yesterday with the US Securities and Exchange Commission the purchase price for its recent acquisitions of Core Informatics and Finesse Solutions, as well as the settlement earlier this year of three patent lawsuits involving DNA sequencing technology from Roche 454 Life Sciences and Illumina.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Paper Gone

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational Biologist James Taylor Dies

Computational biologist James Taylor has died, according to Johns Hopkins University.

Ever Infected

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

PLOS Papers on Hepatocellular Carcinoma Immune Cells, Regulatory Prostate Cancer Risk SNPs, More

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

What's Popular?

In Business News

  1. Thermo Fisher Preliminary Q1 Revenues up 1 to 2 Percent; Firm Withdraws 2020 Guidance

  2. Co-Diagnostics Gets FDA Emergency Use Authorization for Coronavirus Test

  3. BGI, Aid Genomics Partner to Build COVID-19 Testing Lab in Gaza

  4. LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

  5. Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.